Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial.
Shaun G GoodmanPhillippe Gabriel StegYann PoulouinDeepak L BhattVera A BittnerRafael DiazGenevieve GaronRobert A HarringtonJohan Wouter JukemaGaren ManvelianWanda StipekMichael SzarekHarvey D WhiteGregory G Schwartznull nullPublished in: Journal of the American Heart Association (2023)
Keyphrases
- end stage renal disease
- placebo controlled
- study protocol
- newly diagnosed
- phase iii
- chronic kidney disease
- clinical trial
- phase ii
- double blind
- prognostic factors
- peritoneal dialysis
- open label
- randomized controlled trial
- squamous cell carcinoma
- adipose tissue
- radiation therapy
- patient reported outcomes
- patient reported
- rectal cancer